Linagliptin
Linagliptin is a highly potent, selective DPP-4 inhibitor with IC50 of 1 nM.
Product Specifications
CAS Number
668270-12-0
Product Name Alternative
BI 1356
UNSPSC
12352005
Hazard Statement
H315, H319, H335
Target
Autophagy; Dipeptidyl Peptidase; Ferroptosis
Type
Reference compound
Related Pathways
Apoptosis; Autophagy; Metabolic Enzyme/Protease
Applications
Metabolism-sugar/lipid metabolism
Field of Research
Metabolic Disease
Assay Protocol
https://www.medchemexpress.com/Linagliptin.html
Purity
99.91
Solubility
DMSO : 25 mg/mL (ultrasonic; warming; heat to 60°C)
Smiles
O=C1N(C2=C(C(N1CC3=NC(C)=C4C=CC=CC4=N3)=O)N(CC#CC)C(N5CCC[C@@H](N)C5)=N2)C
Molecular Formula
C25H28N8O2
Molecular Weight
472.54
Precautions
H315, H319, H335
References & Citations
[1]Eckhardt M, et al. 8- (3- (R) -aminopiperidin-1-yl) -7-but-2-ynyl-3-methyl-1- (4-methyl-quinazolin-2-ylmethyl) -3,7-dihydropurine-2,6-dione (BI 1356), a highly potent, selective, long-acting, and orally bioavailable DPP-4 inhibitor for the treatment of type 2 d|[2]Thomas L, et al. (R) -8- (3-amino-piperidin-1-yl) -7-but-2-ynyl-3-methyl-1- (4-methyl-quinazolin-2-ylmethyl) -3,7-dihydro-purine-2,6-dione (BI 1356), a novel xanthine-based dipeptidyl peptidase 4 inhibitor, has a superior potency and longer duration of action|[3]Schurmann C, et al. The dipeptidyl peptidase-4 inhibitor linagliptin attenuates inflammation and accelerates epithelialization in wounds of diabetic ob/ob mice. J Pharmacol Exp Ther. 2012 Jul;342 (1) :71-80.|[4]Huan Y, et al. The dual DPP4 inhibitor and GPR119 agonist HBK001 regulates glycemic control and beta cell function ex and in vivo. Sci Rep. 2017 Jun 28;7 (1) :4351.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
Launched
Isoform
DPP-4
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
